Stocks
Aerie Pharmaceuticals IncAERI
HealthcareBiotechnology
A specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of eye diseases, including glaucoma and other retinal conditions. Its lead product, Rhopressa, and follow-on candidate, Roclatan, target intraocular pressure reduction through a novel mechanism. Investors track the company for its pipeline progress and commercial execution in the ophthalmic market.
Congressional Interest in Aerie Pharmaceuticals Inc (AERI)
1 member of Congress has disclosed 1 trade in Aerie Pharmaceuticals Inc (AERI), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
1
Sells
0
Who in Congress Is Trading AERI?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2016-08-22 | JAMES B. RENACCI | buy | $100K-$250K |